Envoy Medical (NASDAQ:COCH) Shares Gap Down – Time to Sell?

Envoy Medical, Inc. (NASDAQ:COCH)’s stock price gapped down before the market opened on Monday. The stock had previously closed at $5.9550, but opened at $5.11. Envoy Medical shares last traded at $6.56, with a volume of 23,099 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. Lake Street Capital initiated coverage on Envoy Medical in a research note on Tuesday, October 6th. They set a “buy” rating and a $25.00 target price for the company. HC Wainwright reiterated a “buy” rating on shares of Envoy Medical in a research report on Tuesday, October 13th. Finally, Loop Capital set a $20.00 price target on shares of Envoy Medical in a research note on Monday, July 27th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Envoy Medical currently has a consensus rating of “Hold” and a consensus price target of $21.67.

Envoy Medical Stock Up 9.4%

The company has a market cap of $502.89 million, a PE ratio of -8.41 and a beta of 1.97. The stock has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $0.69.

Envoy Medical (NASDAQ:COCH) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.10. The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.05 million. As a group, research analysts anticipate that Envoy Medical, Inc. will post -0.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Envoy Medical stock. DSG Capital Advisors LLC bought a new position in Envoy Medical, Inc. (NASDAQ:COCH) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 625,000 shares of the company’s stock, valued at approximately $416,000. DSG Capital Advisors LLC owned 0.81% of Envoy Medical as of its most recent filing with the Securities and Exchange Commission. 8.59% of the stock is owned by institutional investors.

Envoy Medical Company Profile

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.